Newsletter registration

Austria.
Where Your Profits Grow Sky High.

The Upper Austrian startup GENSPEED® Biotech develops a rapid test system for hospital bacteria and periodontal pathogens

GENSPEED®-Technology © GENSPEED® Biotech GmbH

Infections caused by antibiotic-resistant hospital bacteria that occur during hospital stays or infections with periodontal pathogens can result in serious consequences for affected patients. Both the detection of hospital bacteria in hospitals and the detection of periodontal pathogens in the dental field can take several days. The patient samples must either be examined through the use of lengthy in-house analyses or sent to external laboratories. With the rapid tests from GENSPEED® Biotech, hospital bacteria can be detected in the hospital laboratory in just 100 minutes, and periodontal pathogens can be detected in just 20 minutes directly at the dentist's practice. In both cases, rapid diagnosis allows for an immediate, targeted start of treatment. The GENSPEED immediate diagnosis system is a patented technology based on microfluid biochips, miniaturized optical detection and automation. In other words, the sample (e.g. from a nasal smear) is processed using standard methods and dripped into a so-called microfluid chip. No further intervention is required by the user, who can read the test result on the computer after a short time.

More information is available here.

 

Share on Facebook Share on Facebook Share on Twitter Share on Twitter

Testimonials

Events

Meet us at events, seminars and trade shows - worldwide.

Austria Map

Find the perfect location for your company

The "mental closeness" of Austria to its neighbours is an important advantage for establishing new business contacts.

Ericsson Austria

Logo
More testimonials

news from the business location Austria

Zika Virus: Testing for Austria vaccine begins

A promising vaccine for the Zika virus is now being tested by Themis Bioscience GmbH, a specialized biotech company developing prophylactic vaccines against emerging tropical infectious diseases. After recent progress with the development of a Chikungunya vaccine the company succeeded in swiftly adapting their proprietary vaccine technology for their Zika vaccine program. This program is based on a live attenuated recombinant vaccine that promises a fast and effective immune response.

Foreign companies as a driving force for Austria

Austria is a very successful country economically speaking. Only Luxembourg, Ireland and the Netherlands have a higher per capita GDP in the EU. Domestic companies mainly assert themselves as market leaders in small niches, are highly productive and export almost everywhere in the world. This is something which is well known, at least within Austria itself.

More news All blog posts